Weight-Loss drug liraglutide tested in kids as young as 6

NCT ID NCT07590219

Ongoing Disease control Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug liraglutide, combined with healthy lifestyle changes, can help children aged 6 to 12 with severe obesity lose weight and improve heart function. Thirty children will receive either liraglutide injections plus lifestyle advice or lifestyle advice alone for 6 months. Researchers will measure changes in body mass index (BMI) and use advanced heart ultrasound to check for cardiovascular benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liraglutide (Saxenda)
What this could lead to: If it works, this could point toward a medication option to help severely obese children lose weight and improve heart health.
What could go wrong: This is a small, early-phase trial with only 30 children, so results may not apply broadly. Liraglutide can cause nausea, vomiting, and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR FUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

morbid obesity Pediatric Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR FUNCTION CHILDHOOD OBESITY ECHOCARDIOGRAPHY LIRAGLUTIDE SEVERE OBESITY SPECKLE TRACKING

Contacts and locations

Locations

Childrens Institute - University of Sao Paulo

São Paulo, São Paulo, 05403-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.